The weekly litigation news digest is live. Subscribe now

IP Verse

Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)

Patent No. EP3536712 (titled "Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)") was filed by Regeneron Pharmaceuticals on Sep 12, 2012. The application was issued on May 31, 2023.

Patent Summary

UPC Cases New

Latest UPC cases involving this patent.

Case NumberFiling DatePlaintiffProceeding Type
UPC_COA_641/2025Jul 14, 2025Sanofi BiotechnologyAppeal
UPC_COA_646/2025Jul 11, 2025AmgenAppeal
UPC_CFI_534/2025Jun 16, 2025AmgenGeneric
CC_24999/2024May 3, 2024Amgen, Amgen EuropeCounter Claim For Revocation
UPC_CFI_505/2023Jan 10, 2024Sanofi BiotechnologiesInfringement

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
AMGENFeb 29, 2024BIJVANK
AMGENFeb 29, 2024DORRIES
AMGENFeb 29, 2024DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMAN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3536712

REGENERON PHARMACEUTICALS
Application Number
EP19162319A
Filing Date
Sep 12, 2012
Status
Granted And Under Opposition
Apr 28, 2023
Publication Date
May 31, 2023
External Links
Slate, EP3536712B1, Google Patents